Skip to main content

Behind every sample is a life, a life filled with questions. We aim to provide answers.

We offer a complete portfolio inclusive of molecular, biochemical, neuroimmunological, cytogenetic, and pharmacogenomic testing for the diagnosis of neurological conditions. Our broad menu of over 400 neurology tests, powered by 15 distinct methodologies, provides transformative answers that can end your patient’s diagnostic journey.

At Quest Advanced™ Neurology, we know each patient is on a diagnostic journey. We understand and empathize with the uncertainty patients feel, with the questions they ask. No matter where each patient is on the diagnostic journey—and no matter what they’re going through—they all share one thing in common: they crave answers. More than that, they deserve them.

We’re here to provide those answers

Answers that will help patients move forward with clarity and confidence. Answers that will ease them out of the diagnostic journey and onto a path forward, ready for whatever comes next. Informed and empowered.

We aid in helping to eliminate the unknowns

That’s why we continue to expand the breadth of our testing through leading diagnostics in a wide range of specialties, including our exclusive LRP4 antibody testing for myasthenia gravis (MG).

While MG most commonly involves either acetylcholine receptors (AChR) or muscle-specific kinase receptors (MuSK) that ultimately inhibit muscle contraction, some patients with the disorder will test negative for these antibodies.

For these cases, Quest provides another solution: LRP4 antibody testing. LRP4 antibodies are believed to be the third-leading cause of MG and were found in 13% of patients testing negative for other MG antibodies.1 With LRP4 antibody testing, we help you get the diagnosis you need to focus on treatment and patient care.

A comprehensive range of testing

In the United States, 1 in 9 people over 65 has Alzheimer’s disease,2 which currently has no cure. But with early detection, we have more hope to slow and ultimately stop the disease. Quest Advanced Neurology offers industry-leading diagnostics—and we’re constantly working toward less invasive testing in pursuit of early Alzheimer’s detection.

Find out more about how Quest is working to end Alzheimer’s disease and dementia

If you suspect a developmental concern in a pediatric patient, swift detection matters. Research shows that early interventions for ASD and developmental delay can greatly improve a child’s development. For these populations, we offer AAP guidelines-based chromosomal microarray analysis (CMA),3 which has the highest diagnostic yield of any single test for children currently available to clinicians.  

Quest’s exome testing helps to improve diagnosis, monitoring, and treatment of rare disorders. Exome testing is a well-established tool for diagnosing genetic conditions in situations where no targeted gene testing exists, or when targeted genetic testing has failed to identify the cause of disease.4 Testing includes Proband, Duo, Trio, and Reanalysis.

Inborn errors of metabolism (IEM) happen when a genetic defect disrupts the body’s metabolic pathway—causing conditions such as vitamin deficiencies, organic acidemia, and peroxisomal disorders. Because the balance between undertreatment and overtreatment can be precarious, ongoing monitoring is essential. Get the insights you need to manage IEM-derived challenges with our comprehensive genetic test menu and on-demand expertise from genetic counselors.

Neuroimmunological diseases are complex. Testing for them shouldn’t be. We make advanced neuroimmunology testing more accessible and actionable. Our neuroimmunology portfolio includes testing for myasthenia gravis, paraneoplastic syndromes, autoimmune encephalitis, neuromyelitis optica, peripheral neuropathy, and multiple sclerosis. Our expansive test menu includes over 40 antibodies and utilizes gold-standard methodologies, such as CBA, RIA, and line blot.5

COVID-19 may affect brain function in some patients with present or past infection. In fact, up to 86% of COVID-19 patients present with neurological symptoms,6,7,8 and nearly a third of survivors are diagnosed with a neurological or psychiatric disorder within 6 months of infection.9 Our lab tests can help you identify underlying concerns and risks such as encephalopathies and stroke.

Gain insight into a patient’s potential response to medications and optimize their treatment plan and outcomes with one of the most comprehensive test panels available today. The Quest Diagnostics Pharmacogenomics Panel provides information for more than 40 genes—which is particularly helpful for patients taking several medications who may otherwise need multiple panels.

Identify a patient’s unique stroke risk and take action by assessing their metabolic and cardiovascular risk profile. Quest offers a full range of stroke testing that can help inform care plans and treatment monitoring. 

The power of Quest


References

  1. Rivner MH, Quarles BM, Pan JX, et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: a multicenter study. Muscle Nerve. 2020;62(3):333-343. doi:10.1002/mus.26985
  2. Alzheimer’s Association. Facts and figures. Published 2021. Accessed July 26, 2021. https://www.alz.org/alzheimers-dementia/facts-figures
  3. America Academy of Pediatrics. Statement of endorsement: Genetic and metabolic testing on children with global developmental delay. Pediatrics. 2012;129(3):e825-e825. doi:10.1542/peds.2011-3485
  4. Sathirapongsasuti JF, Lee H, Horst BA, et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics. 2011;27(19):2648-2654. doi: 10.1093/bioinformatics/btr462
  5. Stocker W, Probst C, Teegen B, et al. Multiparameter autoantibody screening in the diagnosis of neurological autoimmune diseases. Paper presented at: 1st Congress of the European Academy of Neurology (EAN); June 2015; Berlin, Germany.
  6. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690. doi:10.1001/jamaneurol.2020.1127
  7. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268-2270. doi:10.1056/NEJMc20085973
  8. Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy- associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020;7(11):2221-2230 doi: 10.1002/acn3.51210
  9. Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. doi:10.1016/s2215-0366(21)00084-5